Eurogin is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Artificial Intelligence (AI) is transforming the landscape of medicine — and nowhere is this transformation more promising than in the prevention and management of HPV-related diseases.
From cervical screening to head and neck cancers, AI-driven technologies are opening a new era of precision, prediction, and personalized care. This forum brings together leading experts, clinicians, and data scientists to explore how AI can redefine our approach to screening, diagnosis, and therapeutic decision-making. The integration of deep learning, multimodal data, and real-time image interpretation is not only improving accuracy but also reshaping clinical workflows and healthcare accessibility across diverse settings.
As AI continues to evolve, its integration into clinical practice will demand not only technological innovation but also new ways of thinking about quality, ethics, and global equity in cancer prevention. This forum aims to spark that reflection and inspire the next generation of intelligent, data-driven healthcare solutions.
This session will explore the latest advancements in applying artificial intelligence (AI) to cervical cancer screening. Four leading experts will present cutting-edge developments from international initiatives that leverage AI for image analysis, risk prediction, and automated decision support. Together, these contributions illustrate how AI may reshape screening programs and accelerate progress toward the elimination of cervical cancer.
Head and Neck Cancer (HNC), including HPV-associated oropharyngeal disease and oral potentially malignant disorders, shows rising incidence, late detection, and heavy survivorship burden worldwide. Advances in AI enable risk stratification from clinical and behavioral data; image-based community and dental screening; multimodal prognostic modeling fusing imaging, pathology, and molecular (HPV, genomics) data; and adaptive treatment and follow-up support. Translation lags because datasets remain fragmented, models fail across sites, and predictive uncertainty is rarely communicated, yet crucial for triage and counseling, especially in low-resource settings. This fast-paced forum will focus on trustworthy pathways to embed AI across the HNC continuum. A moderated discussion will synthesize regulation, workflow integration, patient communication, and engaging audience input. Aligned with EUROGIN’s mission to reduce the burden of HPV-related disease through prevention, screening, and translational research, the session broadens the lens to encompass the wider Head and Neck Cancer spectrum while retaining a strong focus on HPV-driven oropharyngeal intersections.
Our field has seen important advances in artificial intelligence over the last decade, which have led to development of classification algorithms for cervical screening and management that are now entering clinical practice. In this session, we will describe general principles of digital imaging and AI algorithm development and show how they are applied to cervical cytology, dual stain cytology, and cervical histology. The speakers will introduce AI-based applications that are at different development stages and particularly focus on how these technologies are already or will be integrated in cervical screening and management algorithms.
For the first time in an international forum, this unique interactive session will bring colposcopy into the era of Artificial Intelligence. Six real clinical cases will be presented by expert colposcopists, each sharing their visual assessment, diagnostic impression, and management decision. In a groundbreaking format, every case will then be submitted live to the audience for diagnostic evaluation, allowing participants to compare their impressions with those of the experts — and finally with the AI model’s prediction displayed in real time. This dynamic exchange will provide an unprecedented opportunity to explore how AI can assist clinicians in improving diagnostic consistency, objectivity, and confidence in managing HPV-related lesions. It will also highlight concordances, discrepancies, and the added value of human–AI collaboration in clinical decision-making. Join us for this live, high-impact experience that bridges clinical expertise, audience participation, and cutting-edge AI technology — a glimpse into the future of colposcopy.
Don't miss out on the the world’s leading international congress on HPV infection and associated cancers. See you in Vienna, March 18-21, 2026